Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Feb 20;11(4):1094–1098. doi: 10.1111/1759-7714.13361

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Clinical outcome of the patient with metastatic lung adenocarcinoma who achieved a pathologic complete response to preoperative immunotherapy. (a) Following treatment with pembrolizumab for two cycles, a partial response (PR) was seen on positron emission tomography‐computed tomography (PET‐CT) scan with a reduction in the size of the tumor in his right upper lung lobe and also in bone metastasis. (b) Pathological results of the resected pulmonary specimens after treatment with pembrolizumab. Magnification, ×200. (c) PD‐L1 assay of the primary lesion on needle biopsy by immunohistochemical (IHC) staining with SP142. Magnification, ×200. (d) Illustrating the timeline of the treatment course of the patient. Pembro, pembrolizumab.